Skip to main content

Table 1 FDA approved drugs in clinical trials for COVID-19 treatment

From: Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2

Zidovudine Linagliptin Chlorpromazine Bevacizumab Sofosbuvir
Hydroxychloroquine Telmisartan Lenalidomide Tinzaparin Vitamina
Lopinavir Anakinra Methotrexate Naproxen Metformin
Tocilizumab Vitaminc Tirofiban Ritonavir Berberine
Sarilumab Zinc Clopidogrel Tacrolimus Licorice
Atazanavir Almitrine Acetylsalicylicacid Celecoxib Bromhexine
Tranexamicacid Sitagliptin Fondaparinux Tofacitinib Minocycline
Alteplase Ciclesonide Ramipril Pirfenidone Lithium
Canakinumab Acalabrutinib Progesterone Hydrogenperoxide Formoterol
Ruxolitinib Etoposide Captopril Sildenafil Indomethacin
Colchicine Ketamine Eculizumab Ixekizumab Selenium
Leflunomide Losartan Sevoflurane Dexmedetomidine Nintedanib
Oxygen Valsartan Nitazoxanide Lipoicacid Spironolactone
Sirolimus Baricitinib Sargramostim Tranilast Imatinib
Povidone-iodine Fluoxetine Ribavirin Adalimumab Estradiol
Fluvoxamine Vitamind Nivolumab Thalidomide Chloroquine
Ibuprofen Bicalutamide Melatonin Fingolimod Azithromycin
Aviptadil Ivermectin Simvastatin Suramin Dexamethasone
Doxycycline Sodiumbicarbonate Dapagliflozin Itraconazole Oseltamivir
Enoxaparin Ibrutinib Amiodarone Mefloquine Amoxicillin
Prazosin Levamisole Verapamil Dalteparin Clavulanate
Isotretinoin Deferoxamine Siltuximab Nadroparin Darunavir
Heparin Methyleneblue Defibrotide Iloprost